Repurposing JAK inhibitors to treat type 1 diabetes

重新利用 JAK 抑制剂治疗 1 型糖尿病

• 批准号: nhmrc : 1145507
• 负责人: A/Pr Helen Thomas
• 金额: $ 64.09万
• 依托单位: St. Vincent's Institute of Medical Research
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2018
• 资助国家: 澳大利亚
• 起止时间: 2018-01-01 至 2021-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/repurposing-jak-inhibitors-1-diabetes/1320460
• 关键词: Repurposing; JAK; inhibitors; treat; type

Type 1 diabetes occurs when the immune system mistakenly attacks and destroys insulin-producing beta cells in the pancreas. Beta cells have to respond to molecules called cytokines for T cells to be able to kill them. We have identified a drug, called a JAK inhibitor, which will block the effects of cytokines on beta cells and cells of the immune system. The goal of this work is perform pre-clinical assessment of this drug, and test whether it has effects on type 1 diabetes in people.

当免疫系统错误地攻击并破坏胰腺中产生胰岛素的 β 细胞时，就会发生 1 型糖尿病。 β 细胞必须对称为细胞因子的分子做出反应，T 细胞才能杀死它们。我们已经发现了一种称为 JAK 抑制剂的药物，它可以阻断细胞因子对 β 细胞和免疫系统细胞的影响。这项工作的目标是对该药物进行临床前评估，并测试它是否对人类 1 型糖尿病有影响。